In clinical, leptin and leptin receptor serves as poor prognostic markers in variant types of cancer including ovarian cancer, colon cancer, AML, gastric cancer, while the prediction of good outcome by the same axis has also been observed in soft tissue cancer. This evidence concerns the gene LEP and ovarian carcinoma.